Advertisement

Cancer Treatment-Related Lung Injury

  • Vickie R. ShannonEmail author
Reference work entry

Abstract

Lung injury associated with cancer therapeutics is often the limiting factor that trumps otherwise successful cancer therapy. Thoracic radiation as well as cancer pharmacotherapeutics, including conventional chemotherapy, molecular targeted agents, and cancer immunotherapies, have been associated with a unique spectrum of histopathologic injury patterns that may involve the lung parenchyma, pleura, airways, and/or pulmonary vasculature. Injury patterns may be idiosyncratic, unpredictable, and highly variable from one agent class to the next. Variability in lung injury patterns within a specific therapeutic class of drugs also occurs, adding to the conundrum. Drug-induced toxicities to the thoracic cavity are infrequent, and early recognition of clinical clues portends a good outcome in most cases. Failure to recognize early clinical signs, however, may result in irreversible and potentially lethal consequences.

This chapter provides an overview of our current knowledge of thoracic complications associated with cancer pharmacotherapies. The review is not intended to be a treatise of all cancer agents that adversely affect the lungs, but rather a discussion of established risk factors and histopathologic patterns of lung injury associated with broad classes of cancer agents. Optimal management strategies, based on existing clinical experience, will also be discussed. Complications associated with thoracic radiation are also reviewed. It is hoped that these discussions will facilitate early recognition and management of treatment-related thoracic complications and, ultimately, better patient outcomes.

Keywords

Drug-induced lung disease Lung injury Toxicity Chemotherapy Immunotherapy Targeted therapy Radiation Pneumonitis Malignancy Pulmonary Interstitial pneumonitis Pleural effusions Respiratory Cancer treatment 

References

  1. 1.
    Bennett WM, Pastore L, Houghton DC. Fatal pulmonary bleomycin toxicity in cisplatin-induced acute renal failure. Cancer Treat Rep. 1980;64:921–4.PubMedGoogle Scholar
  2. 2.
    Azambuja E, Fleck JF, Batista RG, Menna SSB. Bleomycin lung toxicity: who are the patients with increased risk? Pulm Pharmacol Ther. 2005;18:363–6.CrossRefGoogle Scholar
  3. 3.
    Massin F. Busulfan-induced pneumopathy. Rev Mal Respir. 1987;3:3–10.Google Scholar
  4. 4.
    Barlesi F, Villani P, Doddoli C, Gimenez C, Kleisbauer JP. Gemcitabine-induced severe pulmonary toxicity. Fundam Clin Pharmacol. 2004;18:85–91.CrossRefGoogle Scholar
  5. 5.
    Steijfer S. Bleomycin-induced pneumonitis. Chest. 2001;120:617–24.CrossRefGoogle Scholar
  6. 6.
    Vulsteke C, Dierickx D, Verbeken E, Wolter P, Thomas J, Schoffski P. Rituximab-induced fatal interstitial pneumonitis: case report. Leuk Lymphoma. 2010;51:546–8.CrossRefGoogle Scholar
  7. 7.
    Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD. Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy. J Clin Oncol. 2017;35:709–17.CrossRefGoogle Scholar
  8. 8.
    Nishino M, Ramaiya NH, Hatabu H, Hodi FS, Armand PF. PD-1 inhibitor-related pneumonitis in lymphoma patients treated with single-agent pembrolizumab therapy. Br J Haematol. 2016;180:752–5.CrossRefGoogle Scholar
  9. 9.
    Mileshkin L, Prince HM, Rischin D, Zimet A. Severe interstitial pneumonitis following high-dose cyclophosphamide, thiotepa and docetaxel: two case reports and a review of the literature. Bone Marrow Transplant. 2001;27:559–63.CrossRefGoogle Scholar
  10. 10.
    Herrmann J, Yang EH, Iliescu CA, Cilingiroglu M, Charitakis K, Hakeem A, Toutouzas K, Leesar MA, Grines CL, Marmagkiolis K. Vascular toxicities of cancer therapies: the old and the new – an evolving avenue. Circulation. 2016;133:1272–89.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hedhli N, Russell KS. Cardiotoxicity of molecularly targeted agents. Curr Cardiol Rev. 2011;7:221–33.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Wattal S, Rao MS, Chandra GN, Razak UK, Shetty KR. Dasatinib induced cardiac tamponade-a rare association. J Clin Diagn Res. 2017;11:FD03–4.PubMedPubMedCentralGoogle Scholar
  13. 13.
    Krauth MT, Herndlhofer S, Schmook MT, Mitterbauer-Hohendanner G, Schlogl E, Valent P. Extensive pleural and pericardial effusion in chronic myeloid leukemia during treatment with dasatinib at 100 mg or 50 mg daily. Haematologica. 2011;96:163–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Eskazan AE, Soysal T, Ongoren S, Gulturk E, Ferhanoglu B, Aydin Y. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy. Haematologica. 2011;96:e15; author reply e16–17CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Bergeron A, Rea D, Levy V, Picard C, Meignin V, Tamburini J, Bruzzoni-Giovanelli H, Calvo F, Tazi A, Rousselot P. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007;176:814–8.CrossRefGoogle Scholar
  16. 16.
    Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, Bouvaist H, Canuet M, Pison C, Macro M, Poubeau P, Girerd B, Natali D, Guignabert C, Perros F, O’Callaghan DS, Jais X, Tubert-Bitter P, Zalcman G, Sitbon O, Simonneau G, Humbert M. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation. 2012;125:2128–37.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Wilcox BE, Ryu JH, Kalra S. Exacerbation of pre-existing interstitial lung disease after oxaliplatin therapy: a report of three cases. Respir Med. 2008;102:273–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Niho S, Kubota K, Goto K, Yoh K, Ohmatsu H, Kakinuma R, Saijo N, Nishiwaki Y. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer: a phase II study. J Clin Oncol. 2006;24:64–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Liu V, White DA, Zakowski MF, Travis W, Kris MG, Ginsberg MS, Miller VA, Azzoli CG. Pulmonary toxicity associated with erlotinib. Chest. 2007;132:1042–4.CrossRefPubMedGoogle Scholar
  20. 20.
    Saravanan V, Kelly CA. Reducing the risk of methotrexate pneumonitis in rheumatoid arthritis. Rheumatology (Oxford). 2004;43:143–7.CrossRefGoogle Scholar
  21. 21.
    Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133:528–38.CrossRefPubMedGoogle Scholar
  22. 22.
    Akoun G, Cadranel JL, Milleron BJ, D’Ortho MP, Mayaud CM. Bronchoalveolar lavage cell data in 19 patients with drug-associated pneumonitis (except amiodarone). Chest. 1991;99:98–104.CrossRefPubMedGoogle Scholar
  23. 23.
    Stover DE, Zaman MB, Hajdu SI, Lange M, Gold J, Armstrong D. Bronchoalveolar lavage in the diagnosis of diffuse pulmonary infiltrates in the immunosuppressed host. Ann Intern Med. 1984;101:1–7.CrossRefPubMedGoogle Scholar
  24. 24.
    White DA, Kris MG, Stover DE. Bronchoalveolar lavage cell populations in bleomycin lung toxicity. Thorax. 1987;42:551–2.CrossRefPubMedPubMedCentralGoogle Scholar
  25. 25.
    Beinert T, Düll T, Wolf K, Holler E, Vogelmeier C, Behr J, Kolb H. Late pulmonary impairment following allogeneic bone marrow transplantation. J Med Res. 1996;1:343–8.Google Scholar
  26. 26.
    van Barneveld P, Veenstra G, Sleijfer D, van der Mark T, Mulder N, Schraffordt Koops H, Sluiter H, Peset R. Changes in pulmonary function during and after bleomycin treatment in patients with testicular carcinoma. Cancer Chemother Pharmacol. 1985;14:168–71.CrossRefPubMedGoogle Scholar
  27. 27.
    Gore EM, Lawton CA, Ash RC, Lipchik RJ. Pulmonary function changes in long-term survivors of bone marrow transplantation. Int J Radiat Oncol Biol Phys. 1996;36:67–75.CrossRefPubMedGoogle Scholar
  28. 28.
    Theuws JC, Muller SH, Seppenwoolde Y, Kwa SL, Boersma LJ, Hart GA, Baas P, Lebesque JV. Effect of radiotherapy and chemotherapy on pulmonary function after treatment for breast cancer and lymphoma: a follow-up study. J Clin Oncol. 1999;17:3091–100.CrossRefPubMedGoogle Scholar
  29. 29.
    Hirsch A, Vander Els N, Straus DJ, Gomez EG, Leung D, Portlock CS, Yahalom J. Effect of ABVD chemotherapy with and without mantle or mediastinal irradiation on pulmonary function and symptoms in early-stage Hodgkin’s disease. J Clin Oncol. 1996;14:1297–305.CrossRefPubMedGoogle Scholar
  30. 30.
    Bruno B, Souillet G, Bertrand Y, Werck-Gallois MC, So Satta A, Bellon G. Effects of allogeneic bone marrow transplantation on pulmonary function in 80 children in a single paediatric centre. Bone Marrow Transplant. 2004;34:143–7.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Hasleton PS, O’Driscoll BR, Lynch P, Webster A, Kalra SJ, Gattamaneini HR, Woodcock AA, Poulter LW. Late BCNU lung: a light and ultrastructural study on the delayed effect of BCNU on the lung parenchyma. J Pathol. 1991;164:31–6.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    O’Driscoll BR, Hasleton PS, Taylor PM, Poulter LW, Gattameneni HR, Woodcock AA. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. N Engl J Med. 1990;323:378–82.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Beynat-Mouterde C, Beltramo G, Lezmi G, Pernet D, Camus C, Fanton A, Foucher P, Cottin V, Bonniaud P. Pleuroparenchymal fibroelastosis as a late complication of chemotherapy agents. Eur Respir J. 2014;44:523–7.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Akira M, Inoue Y, Kitaichi M, Yamamoto S, Arai T, Toyokawa K. Usual interstitial pneumonia and nonspecific interstitial pneumonia with and without concurrent emphysema: thin-section CT findings. Radiology. 2009;251:271–9.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Cordier JF. Organising pneumonia. Thorax. 2000;55:318–28.CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Drakopanagiotakis F, Paschalaki K, Abu-Hijleh M, Aswad B, Karagianidis N, Kastanakis E, Braman SS, Polychronopoulos V. Cryptogenic and secondary organizing pneumonia: clinical presentation, radiographic findings, treatment response, and prognosis. Chest. 2011;139:893–900.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Raanani P, Segal E, Levi I, Bercowicz M, Berkenstat H, Avigdor A, Perel A, Ben-Bassat I. Diffuse alveolar hemorrhage in acute promyelocytic leukemia patients treated with ATRA – a manifestation of the basic disease or the treatment. Leuk Lymphoma. 2000;37:605–10.CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Tefferi A, Litzow MR, Pardanani A. Long-term outcome of treatment with ruxolitinib in myelofibrosis. N Engl J Med. 2011;365:1455–7.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Beauverd Y, Samii K. Acute respiratory distress syndrome in a patient with primary myelofibrosis after ruxolitinib treatment discontinuation. Int J Hematol. 2014;100:498–501.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Rogers JE, Yang D. Differentiation syndrome in patients with acute promyelocytic leukemia. J Oncol Pharm Pract. 2012;18:109–14.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Luesink M, Jansen JH. Advances in understanding the pulmonary infiltration in acute promyelocytic leukaemia. Br J Haematol. 2010;151:209–20.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Cooper J. Drug-induced lung disease. Adv Intern Med. 1997;42:231–68.Google Scholar
  43. 43.
    Shannon V, Price K. Pulmonary complications of cancer therapy. Anesthesiol Clin North Am. 1998;16:563–85.CrossRefGoogle Scholar
  44. 44.
    Sachdeva A, Matuschak GM. Diffuse alveolar hemorrhage following alemtuzumab. Chest. 2008;133:1476–8.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Hildebrand F, Rosenow EI, Haberman T. Pulmonary complications of leukemia. Chest. 1990;98(5):1233–9.Google Scholar
  46. 46.
    Afessa B, Tefferi A, Litzow MR, Krowka MJ, Wylam ME, Peters SG. Diffuse alveolar hemorrhage in hematopoietic stem cell transplant recipients. Am J Respir Crit Care Med. 2002;166:641–5.CrossRefPubMedPubMedCentralGoogle Scholar
  47. 47.
    Sandler A. Bevacizumab in non small cell lung cancer. Clin Cancer Res. 2007;13:s4613–6.CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF 3rd, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol. 2004;22:2184–91.CrossRefPubMedPubMedCentralGoogle Scholar
  49. 49.
    Huggins JT, Sahn SA. Drug-induced pleural disease. Clin Chest Med. 2004;25:141–53.CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Wohlrab J, Liu M, Anderson E, Kia Noury D. Docetaxel induced pleural effusions [abstract]. Chest. 2002;122:94S–5S.CrossRefGoogle Scholar
  51. 51.
    Procopio G, Verzoni E, Gevorgyan A, Mancin M, Pusceddu S, Catena L, Platania M, Guadalupi V, Martinetti A, Bajetta E. Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology. 2007;73:204–9.CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    Nalluri SR, Chu D, Keresztes R, Zhu X, Wu S. Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis. JAMA. 2008;300:2277–85.CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Godinas L, Guignabert C, Seferian A, Perros F, Bergot E, Sibille Y, Humbert M, Montani D. Tyrosine kinase inhibitors in pulmonary arterial hypertension: a double-edge sword? Semin Respir Crit Care Med. 2013;34:714–24.CrossRefPubMedPubMedCentralGoogle Scholar
  54. 54.
    Abratt RP, Morgan GW. Lung toxicity following chest irradiation in patients with lung cancer. Lung Cancer. 2002;35:103–9.CrossRefPubMedPubMedCentralGoogle Scholar
  55. 55.
    Soultati A, Mountzios G, Avgerinou C, Papaxoinis G, Pectasides D, Dimopoulos MA, Papadimitriou C. Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev. 2012;38:473–83.CrossRefPubMedPubMedCentralGoogle Scholar
  56. 56.
    Szebeni J, Alving CR, Savay S, Barenholz Y, Priev A, Danino D, Talmon Y. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions. Crit Rev Ther Drug Carrier Syst. 2001;18:567–606.PubMedPubMedCentralGoogle Scholar
  57. 57.
    Lv Y, Tang B, Liu X, Xue C, Liu Y, Kang P, Zhang LA. Comparative study of scientific publications in health care sciences and services from Mainland China, Taiwan, Japan, and India (2007–2014). Int J Environ Res Public Health. 2016;13:79.CrossRefGoogle Scholar
  58. 58.
    Markman M. Managing taxane toxicities. Support Care Cancer. 2003;11:144–7.PubMedPubMedCentralGoogle Scholar
  59. 59.
    Rivera NP, Kris MG, Gralla RJ. Syndrome of acute dyspnea related to combined mitomycin plus vinca alkaloid chemotherapy. Am J Clin Oncol. 1995;18:245–50.CrossRefPubMedPubMedCentralGoogle Scholar
  60. 60.
    Hwang SD, Chung BH, Oh EJ, Choi BS, Park CW, Kim YS, Yang CW. Effect of pretransplant rituximab use on posttransplant clinical outcomes in patients with high panel reactive antibody scores. Nephron. 2015;130:239–44.CrossRefPubMedPubMedCentralGoogle Scholar
  61. 61.
    Voog E, Morschhauser F, Solal-Celigny P. Neutropenia in patients treated with rituximab. N Engl J Med. 2003;348:2691–4; discussion 2691–2694CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Byrd JC, Peterson BL, Morrison VA, Park K, Jacobson R, Hoke E, Vardiman JW, Rai K, Schiffer CA, Larson RA. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood. 2003;101:6–14.CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Hillmen P, Robak T, Janssens A, Babu KG, Kloczko J, Grosicki S, Doubek M, Panagiotidis P, Kimby E, Schuh A, Pettitt AR, Boyd T, Montillo M, Gupta IV, Wright O, Dixon I, Carey JL, Chang CN, Lisby S, McKeown A, Offner F, Investigators CS. Chlorambucil plus ofatumumab versus chlorambucil alone in previously untreated patients with chronic lymphocytic leukaemia (COMPLEMENT 1): a randomised, multicentre, open-label phase 3 trial. Lancet. 2015;385:1873–83.CrossRefPubMedPubMedCentralGoogle Scholar
  64. 64.
    Keating MJ, O’Brien S, Albitar M, Lerner S, Plunkett W, Giles F, Andreeff M, Cortes J, Faderl S, Thomas D, Koller C, Wierda W, Detry MA, Lynn A, Kantarjian H. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23:4079–88.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Martin SI, Marty FM, Fiumara K, Treon SP, Gribben JG, Baden LR. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis. 2006;43:16–24.CrossRefPubMedPubMedCentralGoogle Scholar
  66. 66.
    Garcia CA, Wu S. Attributable risk of infection to mTOR inhibitors everolimus and temsirolimus in the treatment of cancer. Cancer Investig. 2016;34:521–30.CrossRefGoogle Scholar
  67. 67.
    Zelenetz AD, Barrientos JC, Brown JR, Coiffier B, Delgado J, Egyed M, Ghia P, Illes A, Jurczak W, Marlton P, Montillo M, Morschhauser F, Pristupa AS, Robak T, Sharman JP, Simpson D, Smolej L, Tausch E, Adewoye AH, Dreiling LK, Kim Y, Stilgenbauer S, Hillmen P. Idelalisib or placebo in combination with bendamustine and rituximab in patients with relapsed or refractory chronic lymphocytic leukaemia: interim results from a phase 3, randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2017;18:297–311.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    O’Brien SM, Lamanna N, Kipps TJ, Flinn I, Zelenetz AD, Burger JA, Keating M, Mitra S, Holes L, Yu AS, Johnson DM, Miller LL, Kim Y, Dansey RD, Dubowy RL, Coutre SE. A phase 2 study of idelalisib plus rituximab in treatment-naive older patients with chronic lymphocytic leukemia. Blood. 2015;126:2686–94.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Jones JA, Robak T, Brown JR, Awan FT, Badoux X, Coutre S, Loscertales J, Taylor K, Vandenberghe E, Wach M, Wagner-Johnston N, Ysebaert L, Dreiling L, Dubowy R, Xing G, Flinn IW, Owen C. Efficacy and safety of idelalisib in combination with ofatumumab for previously treated chronic lymphocytic leukaemia: an open-label, randomised phase 3 trial. Lancet Haematol. 2017;4:e114–26.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Stilgenbauer S, Eichhorst B, Schetelig J, Coutre S, Seymour JF, Munir T, Puvvada SD, Wendtner CM, Roberts AW, Jurczak W, Mulligan SP, Bottcher S, Mobasher M, Zhu M, Desai M, Chyla B, Verdugo M, Enschede SH, Cerri E, Humerickhouse R, Gordon G, Hallek M, Wierda WG. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17:768–78.CrossRefGoogle Scholar
  71. 71.
    Wysham NG, Sullivan DR, Allada G. An opportunistic infection associated with ruxolitinib, a novel janus kinase 1,2 inhibitor. Chest. 2013;143:1478–9.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Palandri F, Polverelli N, Breccia M, Nicolino B, Vitolo U, Alimena G, Cavo M, Vianelli N, Benevolo G. Safety and efficacy of ruxolitinib in myelofibrosis patients without splenomegaly. Br J Haematol. 2016;174:160–2.CrossRefGoogle Scholar
  73. 73.
    Heine A, Brossart P, Wolf D. Ruxolitinib is a potent immunosuppressive compound: is it time for anti-infective prophylaxis? Blood. 2013;122:3843–4.CrossRefGoogle Scholar
  74. 74.
    Offidani M, Corvatta L, Polloni C, Gentili S, Brioni A, Visani G, Galieni P, Brunori M, Alesiani F, Catarini M, Centurioni R, Samori A, Blasi N, Ferranti M, Fraticelli P, Mele A, Rizzi R, Larocca F, Leoni P. Infectious complications in patients with multiple myeloma treated with new drug combinations containing thalidomide. Leuk Lymphoma. 2011;52:776–85.CrossRefGoogle Scholar
  75. 75.
    Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: a systematic review and meta-analysis. Eur J Cancer. 2016;67:21–37.CrossRefGoogle Scholar
  76. 76.
    Jouanguy E, Altare F, Lamhamedi S, Revy P, Emile JF, Newport M, Levin M, Blanche S, Seboun E, Fischer A, Casanova JL. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N Engl J Med. 1996;335:1956–61.CrossRefGoogle Scholar
  77. 77.
    Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, Siegel JN, Braun MM. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med. 2001;345:1098–104.CrossRefPubMedPubMedCentralGoogle Scholar
  78. 78.
    Sakai S, Kauffman KD, Sallin MA, Sharpe AH, Young HA, Ganusov VV, Barber DL. CD4 T cell-derived IFN-gamma plays a minimal role in control of pulmonary Mycobacterium tuberculosis infection and must be actively repressed by PD-1 to prevent lethal disease. PLoS Pathog. 2016;12:e1005667.CrossRefPubMedPubMedCentralGoogle Scholar
  79. 79.
    Hadjiliadis D, Govert JA. Methemoglobinemia after infusion of ifosfamide chemotherapy: first report of a potentially serious adverse reaction related to ifosfamide. Chest. 2000;118:1208–10.CrossRefPubMedPubMedCentralGoogle Scholar
  80. 80.
    Abdel-Rahman O, Fouad M. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Ther Adv Respir Dis. 2016;10:183–93.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Goppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM. Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. Eur J Cancer. 2016;60:210–25.CrossRefPubMedGoogle Scholar
  82. 82.
    Nishino M, Giobbie-Hurder A, Hatabu H, Ramaiya NH, Hodi FS. Incidence of programmed cell death 1 inhibitor-related pneumonitis in patients with advanced cancer: a systematic review and meta-analysis. JAMA Oncol. 2016;2:1607–16.CrossRefPubMedGoogle Scholar
  83. 83.
    Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grunwald V, Kahler KC, Loquai C, Reinmuth N, Steins M, Zimmer L, Sendl A, Gutzmer R. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev. 2016;45:7–18.CrossRefPubMedGoogle Scholar
  84. 84.
    Nishino M, Brais LK, Brooks NV, Hatabu H, Kulke MH, Ramaiya NH. Drug-related pneumonitis during mammalian target of rapamycin inhibitor therapy in patients with neuroendocrine tumors: a radiographic pattern-based approach. Eur J Cancer. 2016;53:163–70.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Nishino M, Chambers ES, Chong CR, Ramaiya NH, Gray SW, Marcoux JP, Hatabu H, Janne PA, Hodi FS, Awad MM. Anti-PD-1 inhibitor-related pneumonitis in non-small cell lung cancer. Cancer Immunol Res. 2016;4:289–93.CrossRefPubMedPubMedCentralGoogle Scholar
  86. 86.
    Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS. PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res. 2016;22:6051–60.CrossRefPubMedPubMedCentralGoogle Scholar
  87. 87.
    Balaji A, Verde F, Suresh K, Naidoo J. Pneumonitis from anti-PD-1/PD-L1 therapy. Oncology (Williston Park). 2017;31:739–46, 754Google Scholar
  88. 88.
    Nishino M, Hatabu H. Programmed death-1/programmed death ligand-1 inhibitor-related pneumonitis and radiographic patterns. J Clin Oncol. 2017;35:1628–9.CrossRefGoogle Scholar
  89. 89.
    Lomax AJ, McGuire HM, McNeil C, Choi CJ, Hersey P, Karikios D, Shannon K, van Hal S, Carr U, Crotty A, Gupta SK, Hollingsworth J, Kim H, Fazekas de St Groth B, McGill N. Immunotherapy-induced sarcoidosis in patients with melanoma treated with PD-1 checkpoint inhibitors: case series and immunophenotypic analysis. Int J Rheum Dis. 2017;20:1277–85.CrossRefGoogle Scholar
  90. 90.
    Berthod G, Lazor R, Letovanec I, Romano E, Noirez L, Mazza Stalder J, Speiser DE, Peters S, Michielin O. Pulmonary sarcoid-like granulomatosis induced by ipilimumab. J Clin Oncol. 2012;30:e156–9.CrossRefPubMedGoogle Scholar
  91. 91.
    Gounant V, Brosseau S, Naltet C, Opsomer MA, Antoine M, Danel C, Khalil A, Cadranel J, Zalcman G. Nivolumab-induced organizing pneumonitis in a patient with lung sarcomatoid carcinoma. Lung Cancer. 2016;99:162–5.CrossRefPubMedGoogle Scholar
  92. 92.
    Kolla BC, Patel MR. Recurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases. J Immunother Cancer. 2016;4:80.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Chiou VL, Burotto M. Pseudoprogression and immune-related response in solid tumors. J Clin Oncol. 2015;33:3541–3.CrossRefPubMedPubMedCentralGoogle Scholar
  94. 94.
    Champiat S, Lambotte O, Barreau E, Belkhir R, Berdelou A, Carbonnel F, Cauquil C, Chanson P, Collins M, Durrbach A, Ederhy S, Feuillet S, Francois H, Lazarovici J, Le Pavec J, De Martin E, Mateus C, Michot JM, Samuel D, Soria JC, Robert C, Eggermont A, Marabelle A. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27:559–74.CrossRefPubMedGoogle Scholar
  95. 95.
    Kluetz PG, Chingos DT, Basch EM, Mitchell SA. Patient-reported outcomes in cancer clinical trials: measuring symptomatic adverse events with the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Am Soc Clin Oncol Educ Book. 2016;35:67–73.CrossRefPubMedGoogle Scholar
  96. 96.
    Barrett DM, Teachey DT, Grupp SA. Toxicity management for patients receiving novel T-cell engaging therapies. Curr Opin Pediatr. 2014;26:43–9.CrossRefPubMedPubMedCentralGoogle Scholar
  97. 97.
    Grupp SA, Kalos M, Barrett D, Aplenc R, Porter DL, Rheingold SR, Teachey DT, Chew A, Hauck B, Wright JF, Milone MC, Levine BL, June CH. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013;368:1509–18.CrossRefPubMedPubMedCentralGoogle Scholar
  98. 98.
    Barrett DM, Singh N, Porter DL, Grupp SA, June CH. Chimeric antigen receptor therapy for cancer. Annu Rev Med. 2014;65:333–47.CrossRefPubMedGoogle Scholar
  99. 99.
    Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014;371:1507–17.CrossRefPubMedPubMedCentralGoogle Scholar
  100. 100.
    Maude SL, Teachey DT, Porter DL, Grupp SA. CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015;125:4017–23.CrossRefPubMedPubMedCentralGoogle Scholar
  101. 101.
    Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011;365:725–33.CrossRefPubMedPubMedCentralGoogle Scholar
  102. 102.
    Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, Olszewska M, Bernal Y, Pegram H, Przybylowski M, Hollyman D, Usachenko Y, Pirraglia D, Hosey J, Santos E, Halton E, Maslak P, Scheinberg D, Jurcic J, Heaney M, Heller G, Frattini M, Sadelain M. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118:4817–28.CrossRefPubMedPubMedCentralGoogle Scholar
  103. 103.
    Fitzgerald JC, Weiss SL, Maude SL, Barrett DM, Lacey SF, Melenhorst JJ, Shaw P, Berg RA, June CH, Porter DL, Frey NV, Grupp SA, Teachey DT. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45:e124–31.CrossRefPubMedPubMedCentralGoogle Scholar
  104. 104.
    Teachey DT, Rheingold SR, Maude SL, Zugmaier G, Barrett DM, Seif AE, Nichols KE, Suppa EK, Kalos M, Berg RA, Fitzgerald JC, Aplenc R, Gore L, Grupp SA. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy. Blood. 2013;121:5154–7.CrossRefPubMedPubMedCentralGoogle Scholar
  105. 105.
    Marks LB, Yu X, Vujaskovic Z, Small W Jr, Folz R, Anscher MS. Radiation-induced lung injury. Semin Radiat Oncol. 2003;13:333–45.CrossRefPubMedGoogle Scholar
  106. 106.
    Movsas B, Raffin TA, Epstein AH, Link CJ Jr. Pulmonary radiation injury. Chest. 1997;111:1061–76.CrossRefGoogle Scholar
  107. 107.
    Cornelissen R, Senan S, Antonisse IE, Liem H, Tan YK, Rudolphus A, Aerts JG. Bronchiolitis obliterans organizing pneumonia (BOOP) after thoracic radiotherapy for breast carcinoma. Radiat Oncol. 2007;2:1–5.CrossRefGoogle Scholar
  108. 108.
    Schweitzer V, Juillard G, Bajada C. Radiation recall dermatitis and pneumonitis in a patient treated with paclitaxel. Cancer. 1995;76:1069–72.CrossRefPubMedGoogle Scholar
  109. 109.
    Schwarte S, Wagner K, Karstens JH, Bremer M. Radiation recall pneumonitis induced by gemcitabine. Strahlenther Onkol. 2007;183:215–7.CrossRefPubMedGoogle Scholar
  110. 110.
    Ding X, Ji W, Li J, Zhang X, Wang L. Radiation recall pneumonitis induced by chemotherapy after thoracic radiotherapy for lung cancer. Radiat Oncol. 2011;6:1–6.CrossRefGoogle Scholar
  111. 111.
    Cottin V, Frognier R, Monnot H, Levy A, DeVuyst P, Cordier JF, Pulmonaires. GdEedRslMO. Chronic eosinophilic pneumonia after radiation therapy for breast cancer. Eur Respir J. 2004;23:9–13.CrossRefGoogle Scholar
  112. 112.
    Hagelstein V, Ortland I, Wilmer A, Mitchell SA, Jaehde U. Validation of the German patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). Ann Oncol. 2016;27:2294–9.CrossRefPubMedPubMedCentralGoogle Scholar
  113. 113.
    Gafter-Gvili A, Gurion R, Raanani P, Shpilberg O, Vidal L. Bendamustine-associated infections-systematic review and meta-analysis of randomized controlled trials. Hematol Oncol. 2017;35(4):424–431. https://www.ncbi.nlm.nih.gov/pubmed/27734524.
  114. 114.
    Ravandi F, O’Brien S. Infections associated with purine analogs and monoclonal antibodies.Blood Rev. 2005;19(5):253–73. https://www.ncbi.nlm.nih.gov/pubmed/15963834.
  115. 115.
    Dias AL, Jain D. Ibrutinib: a new frontier in the treatment of chronic lymphocytic leukemia by Bruton’s tyrosine kinase inhibition. Cardiovasc Hematol Agents Med Chem. 2013;11(4):265–71. https://www.ncbi.nlm.nih.gov/pubmed/24433470.
  116. 116.
    Teh BW, Harrison SJ, Worth LJ, Thursky KA, Slavin MA. Infection risk with immunomodulatory and proteasome inhibitor-based therapies across treatment phases for multiple myeloma: A systematic review and meta-analysis. Eur J Cancer. 2016;67:21–37.  https://doi.org/10.1016/j.ejca.2016.07.025. https://www.ncbi.nlm.nih.gov/pubmed/27592069.

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Pulmonary Medicine, Division of Internal MedicineThe University of Texas at MD Anderson Cancer CenterHoustonUSA

Section editors and affiliations

  • Yenny Cardenas
    • 1
  1. 1.Critical Care DepartmentUniversidad del Rosario Hospital Universitario Fundacion Santa Fe deBogotaColombia

Personalised recommendations